Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.

Banerjee M, Pal R, Pal S

Diabetes, obesity & metabolism8 Oct 2025Cited by 3 (Europe PMC)

PMID41063381DOI10.1111/dom.70187PepBankPUB-41063381

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with biopsy-confirmed MASH, survodutide 2.4 mg/week improved fibrosis compared with placebo in the network meta-analysis.
In plain wordsIn adults with MASH, survodutide 2.4 mg weekly improved liver scarring compared with placebo in a pooled analysis.
Peptide
Survodutide
Outcome
IncreaseFibrosis improvement (at least 1 stage) without worsening steatohepatitis
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
2.4 mg/weekAs given in this study (human).
Source sentences
Summary
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I² = 0%).
2 context sentences(design, population, supporting numbers)
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Report a problemFND-4106338101
02HumanSystematic reviewEfficacy outcome
In adults with biopsy-confirmed MASH, survodutide 4.8-6 mg/week improved fibrosis compared with placebo in the network meta-analysis.
In plain wordsIn adults with MASH, survodutide 4.8-6 mg weekly improved liver scarring compared with placebo in a pooled analysis.
Peptide
Survodutide
Outcome
IncreaseFibrosis improvement (at least 1 stage) without worsening steatohepatitis
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
4.8-6 mg/weekAs given in this study (human).
Source sentences
Summary
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I² = 0%).
2 context sentences(design, population, supporting numbers)
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Report a problemFND-4106338102
03HumanSystematic reviewEfficacy outcome
In adults with biopsy-confirmed MASH, survodutide had the highest ranking for MASH resolution (SUCRA 0.822-0.849), ahead of tirzepatide and higher-dose semaglutide.
In plain wordsIn adults with MASH, survodutide ranked highest of the compared drugs for MASH resolution in a pooled analysis.
Peptide
Survodutide
Outcome
Not applicableSUCRA ranking for MASH resolution without fibrosis worsening
Study
n: not reported in source
Comparator
Tirzepatide, semaglutide
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SUCRA
0.822 to 0.849
survodutide, MASH resolution
Source sentences
Summary
Survodutide exhibited the highest ranking (SUCRA = 0.822-0.849), followed by Tirzepatide (SUCRA = 0.622-0.681) and higher-dose Semaglutide (SUCRA = 0.327) for MASH resolution.
2 context sentences(design, population, supporting numbers)
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Report a problemFND-4106338103
04HumanSystematic reviewEfficacy outcome
In a network meta-analysis in biopsy-confirmed MASH, lower-dose semaglutide showed no benefit for MASH resolution.
In plain wordsIn people with MASH liver disease, lower-dose semaglutide did not improve resolution of the disease.
Peptide
Semaglutide
Outcome
No significant changeMASH resolution without fibrosis worsening
Study
n: not reported in source
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
For MASH resolution, dose-dependent effects led to significant heterogeneity (I² = 73%), with lower-dose Semaglutide demonstrating no benefits
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
Data from five RCTs (N = 1667) were included.
Report a problemFND-4106338106
05HumanSystematic reviewEfficacy outcome
In a network meta-analysis in biopsy-confirmed MASH, tirzepatide (SUCRA 0.622-0.681) ranked below survodutide for MASH resolution and above higher-dose semaglutide.
In plain wordsIn people with MASH liver disease, tirzepatide ranked below survodutide and above higher-dose semaglutide for resolving the disease.
Peptide
Tirzepatide
Outcome
Not applicableMASH resolution ranking (SUCRA)
Study
n: not reported in source
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SUCRA
0.622 to 0.681
MASH resolution
Source sentences
Summary
Tirzepatide (SUCRA = 0.622-0.681)
3 context sentences(design, population, supporting numbers)
Summary · context
Treatment ranking used surface-under the cumulative-ranking curve (SUCRA).
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
Data from five RCTs (N = 1667) were included.
Report a problemFND-4106338107
06HumanSystematic reviewEfficacy outcome
In a network meta-analysis in biopsy-confirmed MASH, higher-dose semaglutide had a SUCRA of 0.327 for MASH resolution, ranking below survodutide and tirzepatide.
In plain wordsIn people with MASH liver disease, higher-dose semaglutide ranked below survodutide and tirzepatide for resolving the disease.
Peptide
Semaglutide
Outcome
Not applicableMASH resolution ranking (SUCRA)
Study
n: not reported in source
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SUCRA
0.327
MASH resolution, higher-dose semaglutide
Source sentences
Summary
higher-dose Semaglutide (SUCRA = 0.327)
3 context sentences(design, population, supporting numbers)
Summary · context
Treatment ranking used surface-under the cumulative-ranking curve (SUCRA).
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
Data from five RCTs (N = 1667) were included.
Report a problemFND-4106338108

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a network meta-analysis in biopsy-confirmed MASH, all active treatments, including semaglutide, improved fibrosis versus placebo.
In plain wordsIn people with MASH liver disease, all tested drugs, including semaglutide, improved liver scarring more than placebo.
Peptide
Semaglutide
Outcome
IncreaseFibrosis improvement without worsening steatohepatitis
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I² = 0%).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
Data from five RCTs (N = 1667) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4106338104
08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In a network meta-analysis in biopsy-confirmed MASH, all active treatments, including tirzepatide, improved fibrosis versus placebo.
In plain wordsIn people with MASH liver disease, all tested drugs, including tirzepatide, improved liver scarring more than placebo.
Peptide
Tirzepatide
Outcome
IncreaseFibrosis improvement without worsening steatohepatitis
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I² = 0%).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was fibrosis improvement (≥1 stage) without worsening steatohepatitis; the secondary outcome was MASH resolution without fibrosis worsening.
Summary · context
A frequentist random-effects network meta-analysis (NMA) was conducted to explore histological efficacy of anti-diabetic agents in biopsy-confirmed MASH without cirrhosis.
Summary · context
Data from five RCTs (N = 1667) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4106338105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.

Summary

Results from this study8

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords